Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 1Hepatic Veno-Occlusive Disease 1Colorectal Neoplasms 1Chemical and Drug Induced Liver Injury 1

Interventions

Specimen Handling 265Magnetic Resonance Spectroscopy 216pembrolizumab 212Carboplatin 173Biopsy 162Cisplatin 155Nivolumab 147Cyclophosphamide 131Paclitaxel 116Radiotherapy 115Gemcitabine 110Bevacizumab 91durvalumab 84Dexamethasone 79Rituximab 74Oxaliplatin 71atezolizumab 67Fluorouracil 66Doxorubicin 65Capecitabine 65Docetaxel 64venetoclax 63Etoposide 63Radiosurgery 58Radiation 57Prednisone 55Ipilimumab 55Cytarabine 55Pemetrexed 54Lenalidomide 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × S-Adenosylmethionine × 90 days × Clear all
NCT06258525 2026-05-06

SAMe in Prevention of Oxaliplatin-associated Liver Injury

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
30 enrolled
Classical hematologyGastrointestinal

Hepatic Veno-Occlusive Disease, Colorectal Neoplasms, Chemical and Drug Induced Liver Injury

NCT07495995 2026-03-31

SAMeMASLDc-02

Cedars-Sinai Medical Center

Phase 2 Not yet recruiting
94 enrolled

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡